Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 9;5(21):4500-4503.
doi: 10.1182/bloodadvances.2021005637.

Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting

Maria A V Marzolini  1   2 , Varun Mehra  3 , Kirsty J Thomson  2 , Eleni Tholouli  4 , Adrian J C Bloor  5 , Anne Parker  6 , Richard Lovell  7 , Kim Orchard  8 , Amy Publicover  9 , Emma Nicholson  10 , John A Snowden  11 , Jennifer Byrne  12 , Anjum Khan  13 , Maria H Gilleece  13 , Gerardo Errico  12 , Sara Lozano  10 , Erin Hurst  9 , Nick Duncan  7 , Jennifer Pirrie  6 , Philip Crea  4 , Ben Carpenter  2 , Antonio Pagliuca  3 , Karl S Peggs  1   2
Affiliations
Comment

Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting

Maria A V Marzolini et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Cumulative incidence of detection of quantifiable CMV according to use of letermovir as prophylaxis. (B) Cumulative incidence of clinically significant CMV infection. (C) Cumulative incidence of preemptive CMV therapy in patients who received letermovir by donor type. (D) Cumulative incidence of clinically significant CMV infection in patients receiving letermovir with at least 14 weeks follow-up according to GVHD severity. UD, unrelated donor.
See this image and copyright information in PMC

Comment on

References

    1. Zamora D, Duke ER, Xie H, et al. . Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138(1):34-43. - PMC - PubMed
    1. Reusser P, Riddell SR, Meyers JD, Greenberg PD.. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5): 1373-1380. - PubMed
    1. Marty FM, Ljungman P, Chemaly RF, et al. . Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433-2444. - PubMed
    1. Chakrabarti S, Mackinnon S, Chopra R, et al. . High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357-4363. - PubMed
    1. Juliusson G, Theorin N, Karlsson K, Frödin U, Malm C.. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant. 2006;37(5):503-510. - PubMed